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Background: Pulmonary complications after hematopoietic
stem cell transplantation (HSCT) are common, and manage-
ment may include a bronchoalveolar lavage (BAL). We reviewed
the medical records of patients (pts) who underwent a BAL and
HSCT at our institution from 1990 to 2002 to determine the
success of BAL and identify factors that may alter the diagnostic
yield of the procedure. Methods: Of 917 pts undergoing HSCT
during this period, 90 pts underwent BAL after HSCT. Multiple
data points were analyzed to determine factors that may identify
a patient population more or less likely to have a diagnostic yield
from a BAL. Results: 114 procedures were performed during
this period. The mean age was 12.5 years (range 0.75–26.2
years). For those who had more than 1 BAL performed, only the
ﬁrst procedure was included in the analysis. The BAL was
performed at a mean of 93 days post-HSCT (range 6–730 days).
The 3 most common signs/symptoms leading to the procedure
were fever (56.7%), hypoxia (48.9%), and abnormal chest aus-
cultation (44.4%). Prior to BAL, 88 pts had radiological imag-
ing; 82 pts (93%) had abnormal ﬁndings. The most common
pre-BAL diagnosis was pneumonia (43.3%) followed by respi-
ratory distress (14.4%). Twenty-nine pts (32.2%) had a negative
BAL. The most common ﬁnding was a bacterial infection
(58.9%), followed by an inﬂammatory process (18.9%), viral
infection (13.3%), and alveolar hemorrhage (12.2%). Of the 44
pts who had concurrent infections, 34 (77%) had positive BAL;
82.2% of pts did not experience any procedural complications,
and 10% experienced hypoxia, generally transient. Sixty-seven
pts were receiving immunosuppressive therapy (IST) at the time
of BAL. Twenty-seven of twenty-nine (93.1%) pts who had a
negative BAL were receiving IST compared to 40/61 (65.6%)
pts who had a positive BAL and were on IST (P  .0046).
Furthermore, the proportion of pts who had grade 2–4 acute
graft-versus-host disease (GVHD) was signiﬁcantly higher in
the BAL negative population (13/29  44.8%) than the BAL
positive group (14/61  23%) [P  .0487]. No other prognostic
factors were identiﬁed for those with grade 2–4 GVHD. Con-
clusions: In our experience, performing a BAL after HSCT is
safe. For patients with grade 2–4 acute GVHD or receiving
IST, the likelihood of a respiratory etiology being identiﬁed by
BAL is lower than those without these risk factors. Therefore, in
this particular patient population, a BAL is less likely to have a
diagnostic yield and may not impact therapy.
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Symptom burden (SB) is the combined impact of all disease- or
therapy-related symptoms on one’s ability to function as one did
before onset of disease or therapy. Patient report of symptoms
following BMT is not well-described. Lack of understanding of
symptoms and SB may result in failure to address symptoms and
return patients to optimum functioning. Purpose: To describe
symptoms and SB in AML/MDS patients undergoing allogeneic
BMT before and after neutrophil engraftment (ﬁrst of 3 consecu-
tive days ANC  500 cells/mm3). Methods: 30 patients with a
mean age of 52.9 years (SD  9.6) rated 19 symptoms on a 0–10
scale twice weekly from baseline before the start of conditioning to
28 days post-BMT using the M. D. Anderson Symptom Inventory.
Results: Mean global symptom severity (GSS) peaked at day 11
post-BMT. The 7 most severe symptoms on day 11 were pain,
drowsiness, lack of appetite, dry mouth, mouth sores, physical
weakness, and fatigue. Mean symptom intensity scores and SDs are
reported in Table 1. There was a signiﬁcant difference (t  4.34,
P .001) between mean GSS at baseline and day11. Neutrophil
engraftment occurred on average 13.7 days (SD  3.00) post-
BMT. There was no signiﬁcant difference (t  0.75, P  .455) in
mean GSS from day 11 to day 15, the ﬁrst post-engraftment
assessment. Mean GSS declined by day 29, but the difference
between the mean GSS on day 11 and day 29 was not signif-
icant (t 1.92, P .060). At day15, only mean pain severity had
declined signiﬁcantly (t  2.48, P  .016) from day 11. At day
29, mean pain and mouth sores severity had declined signiﬁcantly
(t  4.46, P  .001 and t  2.26, P  .031, respectively) from day
11. Conclusions: Patients report various symptoms post-alloge-
neic BMT, with the most severe involving pain, the upper GI tract,
fatigue, and weakness. After engraftment, pain severity declines
rapidly, GI symptoms decline more slowly, and fatigue and weak-
ness do not decline. Most symptoms have not declined signiﬁcantly
a month post-BMT and patients remain burdened by symptoms.
Clinicians should verify with patients the symptoms they are ex-
periencing and intervene to control them. Further research in SB
and in the causative mechanisms of symptoms is needed to improve
BMT treatment outcomes.
Table 1. Mean Symptom Severity Scores
Baseline Day 11 Day 15 Day 29
Symptom Mean, SD Mean, SD Mean, SD Mean, SD
GSS 1.32,1.38 3.08,1.74 2.72,1.91 2.24,1.59
Pain 1.80,2.91 5.30,2.68 3.52,2.84 2.29,2.45
Drowsiness 1.87,2.50 5.20,2.89 4.48,3.00 3.75,3.08
Lack of appetite 1.10,2.22 4.57,3.18 4.14,3.32 3.18,2.88
Dry mouth 0.87,1.61 4.52,3.21 3.97,3.52 2.93,3.21
Mouth sores 0.03,0.18 4.50,3.95 2.93,3.21 0.82,2.06
Physical weakness 2.03,2.55 4.37,2.86 3.83,2.90 3.96,2.76
Fatigue 3.00,2.29 4.20,2.57 4.41,2.78 4.46,2.82
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Adenoviral infections cause signiﬁcant mortality in bone marrow
transplant (BMT) patients and those with protracted therapy-
induced leukopenia. The mortality from adenovirus in the BMT
population approaches 60% and fatalities have been reported in
oncology patients. Cidofovir (CDV) has emerged as a promising
therapy for adenovirus infection, though its efﬁcacy is reported as
low as 31% with renal toxicity up to 50%. There are no published
clinical algorithms guiding initiation of therapy, and the efﬁcacy
and safety of CDV in pediatric oncology patients are ill-deﬁned. A
clinical algorithm was developed reserving CDV therapy for high-
risk patients, deﬁned as: (1) a BMT patient or a patient with
prolonged leukopenia and (2) evidence of dissemination (blood
PCR or recovery of adenovirus from two or more sites) or
evidence of invasive disease (symptoms associated with the site of
adenoviral disease). A retrospective review of pediatric oncology
and BMT patients with adenoviral infection between July 2001 and
July 2004 captured 20 patients: 9 allogeneic BMT, 3 autologous
BMT, and 8 non-BMT. Using the algorithm, 14 were high risk. Of
these, 9 were treated with CDV. All initially cleared their adeno-
virus though 1 died of fungal infection after recrudescence of
adenovirus. All 5 high-risk CDV untreated patients died, 4 with
disseminated adenovirus. CDV treatment signiﬁcantly reduced ad-
enovirus-related mortality in the high-risk group (RR 0.14, P 
.05). Graft-versus-host disease (GVHD) and hemolytic-uremic
syndrome (HUS) were associated with negative outcomes. All 4
patients with HUS died. Seventy-ﬁve percent of those who died
had severe GVHD. The overall mortality was 45% (9/20), of
which 67% (6/9) was due to adenoviral disease, primarily among
high risk, untreated (5/6) patients. All 6 low-risk patients cleared
their infection without CDV treatment, but one recrudesced and
died of adenoviral disease; he met criteria for treatment at recru-
Poster Session II
135BB&MT
